Fig. 4
From: Metformin alters therapeutic effects in the BALB/c tumor therapy model
Establishment of the BALB/c tumor therapy model (BALB-TTM) with chemotherapeutic agents. a The BALB/c 3 T3 cell transformation assay was performed as described earlier. An additional treatment was conducted on day 32 with Doxorubicin (Dox), Doxetaxel (Dtx), Mitomycin C (MMC) or 5-Fluorouracil (5-FU) for 72 h and cells were fixed on day 35. Representative pictures and the number of type-III foci of 3 biological replicates (mean + SD) are shown for different concentrations of b Doxorubicin, c Docetaxel, d Mitomycin C and e 5-Fluorouracil. Statistical differences were calculated with a one-way ANOVA (post-hoc: Bonferroni or Dunnett-T3) with ** = (p < 0.01) and *** = (p < 0.001) vs. control